Ik‐Joo Chung

ORCID: 0000-0003-0479-8067
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Immunotherapy and Immune Responses
  • Lung Cancer Treatments and Mutations
  • Esophageal Cancer Research and Treatment
  • Immune Cell Function and Interaction
  • Cytokine Signaling Pathways and Interactions
  • Ubiquitin and proteasome pathways
  • Metastasis and carcinoma case studies
  • Cancer-related Molecular Pathways
  • Cancer-related gene regulation
  • Cancer Mechanisms and Therapy
  • Cancer Treatment and Pharmacology
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Head and Neck Cancer Studies
  • T-cell and B-cell Immunology
  • Gastrointestinal Tumor Research and Treatment
  • Galectins and Cancer Biology
  • Cancer Immunotherapy and Biomarkers
  • Fibroblast Growth Factor Research
  • Hematopoietic Stem Cell Transplantation
  • Advanced Breast Cancer Therapies
  • Acute Myeloid Leukemia Research
  • Head and Neck Surgical Oncology
  • Epigenetics and DNA Methylation

Chonnam National University Hwasun Hospital
2016-2025

Chonnam National University Hospital
2003-2021

Chonnam National University
2008-2017

Obayashi (Japan)
2014

Kindai University
2014

National Cancer Center Hospital East
2014

GlaxoSmithKline (Japan)
2014

Yeungnam University Medical Center
2012

Hallym University Medical Center
2012

Keimyung University Dongsan Medical Center
2012

Purpose In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) –positive tumors. The role of anti-HER2 agents, lapatinib, this setting and population unclear. Patients Methods TyTAN was a two-part, parallel-group, phase III study patients. An open-label, dose-optimization (n = 12) followed by randomized 261), which patients who were HER2 positive fluorescence situ hybridization (FISH)...

10.1200/jco.2013.53.6136 article EN Journal of Clinical Oncology 2014-05-28

PURPOSE Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia. Based on positive findings perioperative European phase III studies, the PRODIGY study (ClinicalTrials.gov identifier: NCT01515748 ) investigated whether neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery adjuvant could improve outcomes versus treatment Korean patients with LAGC. PATIENTS AND METHODS Patients 20-75 years of age, Eastern Cooperative...

10.1200/jco.20.02914 article EN cc-by-nc-nd Journal of Clinical Oncology 2021-06-16

Immunotherapy has revolutionized the clinical outcomes of intractable cancer patients. Little is known about intestinal nonpathogenic bacterial composition hepatocellular carcinoma (HCC) patients treated by immunotherapy.To determine whether there a correlation between gut and prognosis in HCC patients.From September 2019 to March 2020, we prospectively collected fecal samples examined microbiome 8 advanced with nivolumab as second- or third-line systemic treatment. Fecal were before start...

10.3748/wjg.v27.i42.7340 article EN cc-by-nc World Journal of Gastroenterology 2021-11-10

ABSTRACT Enhancer of zeste homolog 2 (EZH2) catalyzes trimethylation histone H3 lysine 27 (H3K27me3) and its demethylation is catalyzed by UTX. EZH2 levels are frequently elevated in breast cancer have been proposed to control gene expression through regulating repressive H3K27me3 marks. However, it not fully established whether cancers with different H3K27me3, UTX exhibit biological behaviors. Levels their prognostic significance were evaluated 146 cases cancer. higher HER2‐negative...

10.1002/mc.22188 article EN Molecular Carcinogenesis 2014-07-07

Abstract Background Clinical studies, with a proper scientific design, on the impact of disclosing prognosis patient's psychological or physical conditions are rare. We investigated effect patient awareness terminal status survival and quality life (QoL) in palliative care setting. Methods This is prospective cohort study patients cancer. Patients cancer at unit were enrolled consecutively. The patients' their was determined using semistructured interview. Sociodemographic clinical...

10.1002/pon.3275 article EN Psycho-Oncology 2013-03-15

<h3>Background and aims</h3> 90K, a tumour-associated glycoprotein, interacts with galectins has roles in host defence by augmenting the immune response, but serum 90K level was suggested to indicate poor prognosis several cancers. The cellular mechanisms of action on colorectal cancer (CRC) cell motility its effect CRC progression were investigated. <h3>Methods</h3> impact analysed combining cultures, vitro assays, immunohistochemistry. <h3>Results</h3> Secreted suppresses invasion, this is...

10.1136/gut.2009.194068 article EN Gut 2010-06-25

KITENIN was previously reported to promote metastasis in mouse colon tumour models; however, the signalling mechanism of at cellular level unknown. Here functional role with respect colorectal cancer (CRC) cell invasion and its expression CRC tissues were investigated.The effect on motility analysed a migration assay upon overexpression knockdown. Immunoprecipitation used elucidate binding partners, immunohistochemistry study levels.KITENIN enhanced rat intestinal epithelial cells, whereas...

10.1136/gut.2008.150938 article EN Gut 2008-07-24

Abstract The prognostic relevance of tumor human papillomavirus (HPV) status in anal squamous cell carcinoma (SCC) had not been previously investigated, although its to cervical, head and neck SCC is known. We retrospectively evaluated outcomes 47 patients with treated combined chemoradiotherapy (CCRT) determined HPV by DNA chip method p16 expression immunohistochemistry (IHC) from paraffin‐embedded tissues. median age was 65 years (range, 44–90 years). Sixteen (34%) were diagnosed T stage 3...

10.1002/ijc.25825 article EN International Journal of Cancer 2010-12-02

Abstract Galectin 3-binding protein (LGALS3BP, also known as 90K) is a multifunctional glycoprotein involved in immunity and cancer. However, its precise role colon inflammation tumorigenesis remains unclear. Here, we showed that Lgals3bp −/− mice were highly susceptible to colitis tumorigenesis, accompanied by the induction of inflammatory responses. In acute colitis, NF-κB was activated mice, leading excessive production pro-inflammatory cytokines, such IL-6, TNFα, IL-1β. Mechanistically,...

10.1038/s41420-021-00447-7 article EN cc-by Cell Death Discovery 2021-04-06

Abstract Background Increased Galectin 3‐binding protein (LGALS3BP) serum levels have been used to assess hepatic fibrosis stages and the severity of hepatocellular carcinoma (HCC). Considering crucial role transforming growth factor‐β1 (TGF‐β1) in emergence these diseases, present study tested hypothesis that LGALS3BP regulates TGF‐β1 signaling pathway. Methods The expression TGFB1 were analyzed patients with metabolic dysfunction‐associated steatohepatitis (MASH) HCC. Multiple omics...

10.1002/cac2.12600 article EN cc-by-nc-nd Cancer Communications 2024-07-28

Although a second stem cell transplantation (SCT) can be used as salvage therapy in patients with relapsing leukemia after SCT, most of these have poor outcome. We tried clinical vaccination using monocyte-derived dendritic cells (DCs) pulsed leukemic lysates to treat acute myeloid (AML) autologous SCT. To generate DCs, CD14+ isolated from peripheral blood products were cultured AIM-V the presence GM-CSF and IL-4. Adding TNF-alpha on day 6 induced maturation which harvested 8 or 9. The DCs...

10.1002/jca.10080 article EN Journal of Clinical Apheresis 2004-01-01

Survivin, a member of inhibitors apoptosis, has been found in various human cancers. Its expression is associated with tumor progression and adverse outcome. Angiogenesis an essential process for the primary to grow invade adjacent normal structures. Angiogenic factors such as vascular endothelial growth factor induce survivin cells. The current study was designed investigate possible role status angiogenesis gastric cancer.In this study, we conducted immunohistochemical investigation 106...

10.1097/01.meg.0000230086.83792.56 article EN European Journal of Gastroenterology & Hepatology 2006-08-04

Abstract CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary and multidrug resistance, but its clinical prognostic significance not clearly identified. This study examined 37 adult de novo AML patients t(8:21). was expressed 25 cases (67.6%). Complete remission (CR) rates were similar both groups (91.7% vs. 88.7%; P = 0.73), the relapse differed considerably (60% 25%; 0.02). The median duration of disease‐free survival (DFS) significantly shorter CD56+...

10.1002/ajh.20739 article EN American Journal of Hematology 2006-09-19

We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized lysates. CD14+ cultured presence GM-CSF IL-4. On day 6, immature DCs pulsed cell lysates, then maturation was induced addition a cytokine cocktail. There no differences phenotypic expressions mature generated CD138+ lysates or total In optimization concentration 10 µg/mL...

10.1080/10428190701583975 article EN Leukemia & lymphoma/Leukemia and lymphoma 2007-01-01

This study was performed to determine the feasibility and safety of salvage chemotherapy, using docetaxel cisplatin in 5-fluorouracil (5-FU) cisplatin-pretreated esophageal cancer.Patients with metastatic or recurrent squamous cell carcinoma that had previously been treated 5-FU chemotherapy chemoradiotherapy were eligible for this study. Docetaxel (70 mg/m²) (75 given as a 1-hour intravenous infusion on day 1, treatment repeated every 3 weeks.Thirty-eight male patients enrolled, 35...

10.1097/coc.0b013e3181bead92 article EN American Journal of Clinical Oncology 2010-03-27
Coming Soon ...